439 related articles for article (PubMed ID: 12950442)
21. Globus pallidus, but not entopeduncular nucleus, 6-OHDA-induced lesion attenuates L-Dopa-induced dyskinesia in the rat model of Parkinson's disease.
Marin C; Bonastre M; Fuentes M; Mullol J
Pharmacol Biochem Behav; 2020 Oct; 197():173013. PubMed ID: 32758524
[TBL] [Abstract][Full Text] [Related]
22. Normalization of glutamate decarboxylase gene expression in the entopeduncular nucleus of rats with a unilateral 6-hydroxydopamine lesion correlates with increased GABAergic input following intermittent but not continuous levodopa.
Nielsen KM; Soghomonian JJ
Neuroscience; 2004; 123(1):31-42. PubMed ID: 14667439
[TBL] [Abstract][Full Text] [Related]
23. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia.
Vila M; Marin C; Ruberg M; Jimenez A; Raisman-Vozari R; Agid Y; Tolosa E; Hirsch EC
J Neurochem; 1999 Jul; 73(1):344-52. PubMed ID: 10386987
[TBL] [Abstract][Full Text] [Related]
24. Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats.
Aristieta A; Ruiz-Ortega JA; Miguelez C; Morera-Herreras T; Ugedo L
Neurobiol Dis; 2016 May; 89():88-100. PubMed ID: 26852950
[TBL] [Abstract][Full Text] [Related]
25. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
[TBL] [Abstract][Full Text] [Related]
26. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
[TBL] [Abstract][Full Text] [Related]
27. l-dopa-induced dyskinesias in unilateral 6-hydroxydopamine-lesioned rats are not modified by excitotoxic lesion of the entopeduncular nucleus and substantia nigra pars reticulata.
Gago B; Marin C; Rodríguez-Oroz MC; Obeso JA
Synapse; 2013 Jul; 67(7):407-14. PubMed ID: 23404474
[TBL] [Abstract][Full Text] [Related]
28. Intrastriatal mesencephalic grafts affect neuronal activity in basal ganglia nuclei and their target structures in a rat model of Parkinson's disease.
Nakao N; Ogura M; Nakai K; Itakura T
J Neurosci; 1998 Mar; 18(5):1806-17. PubMed ID: 9465005
[TBL] [Abstract][Full Text] [Related]
29. Effect of deep brain stimulation on levodopa-induced dyskinesias and striatal oscillatory local field potentials in a rat model of Parkinson's disease.
Alam M; Capelle HH; Schwabe K; Krauss JK
Brain Stimul; 2014; 7(1):13-20. PubMed ID: 24126192
[TBL] [Abstract][Full Text] [Related]
30. Effect of subthalamic nucleus lesions in a 6-hydroxydopamine-induced rat parkinsonian model: behavioral and biochemical studies.
Hwang YS; Shim I; Lee BB; Chang JW
J Neurosurg; 2006 Aug; 105(2):284-7. PubMed ID: 17219835
[TBL] [Abstract][Full Text] [Related]
31. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
Armentero MT; Fancellu R; Nappi G; Bramanti P; Blandini F
Neurobiol Dis; 2006 Apr; 22(1):1-9. PubMed ID: 16289868
[TBL] [Abstract][Full Text] [Related]
32. AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
Périer C; Marin C; Bonastre M; Tolosa E; Hirsch EC
Eur J Neurosci; 2002 Dec; 16(11):2236-40. PubMed ID: 12473092
[TBL] [Abstract][Full Text] [Related]
33. Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study.
Marin C; Aguilar E; Mengod G; Cortés R; Obeso JA
Eur J Neurosci; 2007 Jan; 25(1):259-69. PubMed ID: 17241287
[TBL] [Abstract][Full Text] [Related]
34. High frequency stimulation of subthalamic nucleus results in behavioral recovery by increasing striatal dopamine release in 6-hydroxydopamine lesioned rat.
He Z; Jiang Y; Xu H; Jiang H; Jia W; Sun P; Xie J
Behav Brain Res; 2014 Apr; 263():108-14. PubMed ID: 24462728
[TBL] [Abstract][Full Text] [Related]
35. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
36. Effect of ipsilateral subthalamic nucleus lesioning in a rat parkinsonian model: study of behavior correlated with neuronal activity in the pedunculopontine nucleus.
Jeon MF; Ha Y; Cho YH; Lee BH; Park YG; Chang JW
J Neurosurg; 2003 Oct; 99(4):762-7. PubMed ID: 14567613
[TBL] [Abstract][Full Text] [Related]
37. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
38. Fos expression following activation of the ventral pallidum in normal rats and in a model of Parkinson's Disease: implications for limbic system and basal ganglia interactions.
Turner MS; Gray TS; Mickiewicz AL; Napier TC
Brain Struct Funct; 2008 Sep; 213(1-2):197-213. PubMed ID: 18663473
[TBL] [Abstract][Full Text] [Related]
39. Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease.
Orieux G; Francois C; Féger J; Yelnik J; Vila M; Ruberg M; Agid Y; Hirsch EC
Neuroscience; 2000; 97(1):79-88. PubMed ID: 10771341
[TBL] [Abstract][Full Text] [Related]
40. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
Ochi M; Shiozaki S; Kase H
Neuroscience; 2004; 127(1):223-31. PubMed ID: 15219684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
